Identifying hub genes in response to ustekinumab and the impact of ustekinumab treatment on fibrosis in Crohn’s disease
IntroductionCrohn’s disease (CD) is a chronic inflammatory disease. Approximately 50% of patients with CD progressed from inflammation to fibrosis. Currently, there are no effective drugs for treating intestinal fibrosis. Biologic therapies for CD such as ustekinumab have benefited patients; however...
Spremljeno u:
| Glavni autori: | , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Frontiers Media S.A.
2024-05-01
|
| Serija: | Frontiers in Immunology |
| Teme: | |
| Online pristup: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1401733/full |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|